Free Trial Program for Hemophilia A Patients | NUWIQ

Factor My Way™ Free Trial Program

The Factor My Way Free Trial Program is a unique opportunity for Hemophilia A patients and their providers to experience the safety, efficacy and convenience of NUWIQ at no cost.

If your patients are currently using another FVIII product, or if they’re not currently using factor treatment, you may want to consider NUWIQ.

With the NUWIQ Free Trial Program, eligible Hemophilia A patients can receive treatment with NUWIQ (not to exceed 6 doses or not exceed approximately 20,000 IUs) at no cost, shipped directly to the patient and administered under your care and supervision.

There’s never been a better time to try NUWIQ and see if it’s right for you and your patients.

3 Steps to Enroll

Download and complete the Factor My Way Free Trial Program application form with your patient.
Write and hand your patient a prescription for NUWIQ
You or your patient fax the completed form and NUWIQ prescription to the Factor My Way Support Center at 1-800-554-6744.

Indications and Important Safety Information for NUWIQ .

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ .

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Usage

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Please see NUWIQ full Prescribing Information. Instructions For Use

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)